<DOC>
	<DOCNO>NCT00125723</DOCNO>
	<brief_summary>The purpose study assess impact first subsequent cycle pegfilgrastim neutropenia event ( hospitalization , dose reduction delay ) patient receive myelosuppressive chemotherapy .</brief_summary>
	<brief_title>FIRST - Study Pegfilgrastim Administered First Subsequent Cycles Myelosuppressive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Pathologically confirm diagnosis follow malignancy : breast , nonHodgkin 's lymphoma ( NHL ) , Hodgkin 's disease , ovarian , colorectal , lung Planned administration new myelosuppressive every 14 ( q14 ) , q21 , q28 day chemotherapy Written inform consent participation study studyspecific procedure perform , include screen registration Exclusion Criteria : Planned concomitant therapeutic radiation Diagnosis acute chronic leukemia myelodysplastic syndrome Prior stemcell transplantation ( include bonemarrow transplantation ) Medical diagnosis chronic neutropenia cause related cancer Current cytotoxic , biologic , immunologic therapy unrelated condition Subject active infection require treatment Known HIVpositive subject Subject childbearing potential evidently pregnant ( e.g. , positive HCG test ) breast feed Subject childbearing potential use adequate contraceptive precaution Known sensitivity E. coli derive drug product ( e.g. , filgrastim , HUMULIN速 insulin , Lasparaginase , HUMATROPE速 growth hormone , INTRON A速 ) Any psychiatric , addictive kind disorder compromise ability subject give write informed consent and/or comply study protocol procedure Subject currently enrol , yet complete least 30 day since end another device drug trial ( ) receiving , plan receive , investigational agent ( ) approve Food Drug Administration ( FDA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase 4 Clinical Trial</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Neulasta速</keyword>
	<keyword>Oncology</keyword>
	<keyword>Malignancy</keyword>
</DOC>